JP Morgan Healthcare Conference
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Geneoscopy, OraSure Technologies
Highlights from the fourth day included Geneoscopy's plans to increase access to its ColoSense colorectal cancer screening test through its partnership with Labcorp.
JP Morgan Healthcare Conference, Day 3: Grail, Ultima Genomics, Seer, GeneDx, Quanterix
Highlights from the third day included Quanterix's announcement of a new protein detection platform, to be launched later this year.
At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
Premium
The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.
Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Jan 15, 2025
Jan 15, 2025
Jan 14, 2025
Jan 14, 2025
Jan 14, 2025
Jan 14, 2025